Jun Li is a Nephrology physician. ClinicalTrials.gov lists 44 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
139 Centre St Ste 703
New York, NY 100134557
Telephone
212-966-0808Provider last certified this registry record 10 Jul 2023.
Clinical trials
- Colorectal Adenoma Cohort
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- SFEE Diet Management for Gestational Diabetes Mellitus
Sponsor: Ji Jing
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20257 payments
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
42.8%Angiotensin receptor blocker (ARB)8.5%Losartan Potassium57%Olmesartan Medoxomil27%Irbesartan5%Filspari5%Telmisartan4%Edarbi3%Part D<11 patientsCalcium channel blocker6.5%Amlodipine Besylate56%Nifedipine Er41%Diltiazem Hcl3%Part D<11 patients+ 13 more classes in this area
Metabolism & gastrointestinal
23.3%SGLT2 inhibitor5.2%Farxiga85%Jardiance9%Dapagliflozin6%Part D<11 patientsVitamin D3 Analog4.7%Calcitriol76%Rayaldee24%Part D≥54 patients+ 14 more classes in this area
Musculoskeletal
10.2%Xanthine oxidase inhibitor9.3%Allopurinol96%Febuxostat4%Part D<11 patientsNonsteroidal Anti-inflammatory Drug0.9%Diclofenac Epolamine64%Diclofenac Sodium36%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”